ICMJE DISCLOSURE FORM

Date: December 21/2022 Your Name: Hidekatsu Nakai

Manuscript Title: Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer

Manuscript number (if known): ATM-22-6389

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>✓</u> None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	✓None	
	any entity (if not indicated	_	
	in item #1 above).		
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	✓None
	manuscript writing or	
	educational events	
6		<u>✓</u> None
7	Support for attending meetings and/or travel	<u>✓</u> None
8	Patents planned, issued or	<u>✓</u> None
	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>✓</u> None
10	<u>'</u>	401
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>✓</u> None
11	Stock or stock options	<u>✓</u> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>✓</u> None
13	Other financial or non- financial interests	<u>✓</u> None

Please summarize the above conflict of interest in the following box:

Hidekatsu Nakai has no conflict of interest regarding to this work.	

Please place an "X" next to the following statement to indicate your agreement:

 \underline{X} I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: December 21/2022

Your Name: Noriomi Matsumura

Manuscript Title: Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer

Manuscript number (if known): ATM-22-6389

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>✓</u> None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca	Research grant for a study of ovarian cancer
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

_	D	A - + 7	1t
5	Payment or honoraria for	AstraZeneca	lecture fee
	lectures, presentations,	Takeda Pharmaceutical	lecture fee
	speakers bureaus,	Chugai Pharmaceutical	lecture fee
	manuscript writing or		
	educational events		
6	Payment for expert	<u>✓</u> None	
	testimony		
7	Support for attending meetings and/or travel	✓ None	
8	Detents planted issued as		
8	Patents planned, issued or	<u>✓</u> None	
	pending		
9	Participation on a Data	<u>✓</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	<u>✓</u> None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>✓</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	✓None	
	services		
13	Other financial or non- financial interests	✓None	
_			

Please summarize the above conflict of interest in the following box:

Noriomi Matsumura received a research grant from AstraZeneca. Noriomi Matsumura also received lecture fees from AstraZeneca, Takeda Pharmaceutical, and Chugai Pharmaceutical.	

Please place an "X" next to the following statement to indicate your agreement:

 \underline{X} I certify that I have answered every question and have not altered the wording of any of the questions on this form.